Answers are grounded in this paper and cite their sources.
BACKGROUND: Adjuvant treatment decisions for patients with small (T ≤ 1 cm), node-negative, human epidermal growth factor receptor 2 (HER2)-positive breast tumors remain challenging, particularly regarding whether oral chemotherapy is comparable to intravenous regimens. We therefore conducted a phase II trial evaluating the efficacy and safety of an oral chemotherapy plus trastuzumab regimen in this population. PATIENTS AND METHODS: on days 1, 8, and 15 every 3 weeks) plus trastuzumab, followed by trastuzumab monotherapy for a total of 12 months of therapy. The primary endpoint was disease-free survival (DFS). The secondary end points were distant disease-free survival (DDFS), overall survival (OS), and safety. This study is registered with ClinicalTrials.gov (NCT04296162). RESULTS: The analysis population included 182 patients, of whom 81% had tumors measuring ≤ 0.5 cm and 74% had hormone receptor (HR)-negative disease. Of the 181 treated patients, 176 (97.2%) received capecitabine and 5 (2.8%) vinorelbine, with agent selection at the physician's discretion. After a median follow-up of 5.7 years (range, 1.0-6.2 years), the 5-year DFS rate was 97.3% (90% Confidence interval [CI], 94.4-98.7). The lower bound of the 90% CI exceeded the prespecified threshold of 92%, meeting the primary endpoint. Among the 6 observed invasive disease events, 2 involved distant metastasis, 3 involved local or regional recurrence, and 1 involved contralateral breast cancer. Among the secondary endpoints, the 5-year DDFS rate was 97.2%, with a 5-year OS rate of 100% (no deaths) during follow-up. Among the 176 patients treated with capecitabine, the most common capecitabine-related adverse event (AE) was hand-foot syndrome, which occurred in 66.5% of patients, with 8.0% of patients experiencing a grade 3 event. CONCLUSIONS: Among women with HER2-positive, node-negative breast tumors measuring ≤ 1 cm, capecitabine-based oral chemotherapy plus 1 year of trastuzumab was associated with a low risk of cancer recurrence and favorable toxicity in this single-arm cohort, supporting further prospective evaluation.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: